About Metanoi Therapeutics
Metanoi Therapeutics is a Healthcare company based in Atlanta (United States) founded in 2019. It develops patented oral treatments targeting cancer cells in humans and veterinary markets. It operates on a B2B and Product Sales model. Metanoi Therapeutics offers products and services including VET001 and MET001. Its focus areas include Biotechnology, Oncology, Cancer Therapeutics and Veterinary. Its legal entity is Metanoi Therapeutics, Inc. Similar companies include TScan Therapeutics, Lyell Immunopharma and GigaGen; 3 of its 3 listed similar companies have raised funding.
Company details
Metanoi Therapeutics creates innovative, non-toxic oral therapies that selectively deplete nutrients in cancer cells, leading to their destruction while sparing healthy tissue. The company focuses on oncology for both humans and animals, with products like VET001 for veterinary use and MET001 for human trials. They conduct preclinical studies and seek FDA approvals to enter markets, providing complementary treatments alongside standard therapies.
- Headquarters Atlanta, United States
- SectorsHealthcare
- Email••••••••
- Website metanoitherapeutics.com
- Legal Name Metanoi Therapeutics, Inc.
Products & Services of Metanoi Therapeutics
Metanoi Therapeutics offers a comprehensive portfolio of products and services, including VET001 and MET001.
Oral therapy for treating cancer in dogs through nutrient depletion.
Oral therapy targeting human cancers by inducing cell death.
Similar companies to Metanoi Therapeutics
Metanoi Therapeutics has 3 listed similar companies in our database, 3 of them funded. They include TScan Therapeutics, Lyell Immunopharma and GigaGen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| lyell.com | 2018 | San Francisco, United States | $493M | 224 | CAR-T and TIL immunotherapies for solid tumors are developed. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. |
Detailed similar companies of Metanoi Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Metanoi Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Metanoi Therapeutics
Metanoi Therapeutics was founded in 2019.
Metanoi Therapeutics is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Metanoi Therapeutics creates innovative, non-toxic oral therapies that selectively deplete nutrients in cancer cells, leading to their destruction while sparing healthy tissue. The company focuses on oncology for both humans and animals, with products like VET001 for veterinary use and MET001 for human trials. They conduct preclinical studies and seek FDA approvals to enter markets, providing complementary treatments alongside standard therapies.
Metanoi Therapeutics's top competitors include Lyell Immunopharma, GigaGen and TScan Therapeutics.
Metanoi Therapeutics offers VET001 and MET001.
Metanoi Therapeutics operates through Metanoi Therapeutics, Inc..